On Thursday, Uganda confirmed an outbreak of the Ebola virus in its capital city Kampala, with the first confirmed patient dying from it a day before. As per the new developments, the officials are now preparing to deploy a trial vaccine to put an end to this outbreak.
Groups of scientists are working on the vaccine and deployment of more than 2,000 doses of a candidate vaccine against the Sudan strain of Ebola has been planned and confirmed by the Uganda Virus Research Institute. As per the World Health Organization (WHO), Uganda has access to 2,169 doses of trial vaccine. For now, however, there are no approved vaccines for the strain and officials are still investigating the source of the outbreak.
The WHO had also allocated $1 million from its contingency fund for emergencies to support quick action and contain the outbreak in the country.
On Wednesday, the Sudan strain of Ebola killed a nurse employed at Kampala's main referral hospital. It is after his death that Ebola was declared an outbreak in the country. Post-mortem samples too have confirmed the Sudan Ebola Virus Disease and at least 44 contacts of the deceased man have been listed for tracing. 30 of these are health workers.
Ebola is a highly infectious hemorrhagic fever, which is transmitted through contact with bodily fluids and tissue. Symptoms include headache, vomiting of blood, muscle pains and bleeding.
it was in the late 2022, when Uganda had last suffered an Ebola outbreak. It killed 55 of the 143 people who were infected and was declared over on January 11, 2023.
As per the WHO, Ebola virus disease (EVD) is a rare but severe illness in humans and is often fatal. People can get infected with the virus if they touch an infected animal when preparing food, or touch body fluids of an infected person such as saliva, urine, faeces or semen, or things that have body fluids of an infected person like clothes or sheets.
Ebola enters the body through cuts in the skin or when one is touching their eyes, nose or mouth. Early symptoms include fever, fatigue and headache.
It was first discovered in 1976 in two simultaneous outbreak, when in Nzara, South Sudan and other in Yambuku, Democratic Republic of Congo. The latter occurred near a village near the Ebola River, which is where it gets its name from.
It is highly infectious and transmissible disease, in fact, there have been cases of health-care workers who have frequently been infected while treating patients with suspected or confirmed Ebola. This occurs through close contact with patients when infection control precautions are not practiced strictly.
Cases of people conducted burial ceremonies, involving direct contact with the body of the deceased too can lead to the transmission of Ebola. Even after the long suffering and recovery, there is a possibility of sexual transmission. Pregnant women who get acute Ebola and recover may still carry the virus in their breastmilk, or in pregnancy related fluids and tissues.
Credit: AI
Young adults who believe vaping is safer than smoking may be in for some surprising news. According to a new study, vape users presented reduced fitness and impaired blood vessel function similar to traditional cigarette smokers.
The research, published in the peer-reviewed journal ERJ Open Research, compared healthy adults aged 18 to 30 and found that both regular vapers and smokers had around 15% lower exercise capacity than people who had never smoked or vaped.
The study involved 75 healthy young adults divided into three groups: non-smokers/non-vapers, cigarette smokers, and regular vapers who had never smoked.
Participants completed an incremental cycling test while researchers measured heart and lung function, oxygen activity, blood lactate levels, and overall vascular health.
Researchers also observed equally poor blood vessel function, reduced breathing efficiency during exercise, and early muscle fatigue in both those who vaped and smoked.
At peak exercise, both smokers and vapers showed significantly lower oxygen uptake and reached exhaustion sooner than non-users.
They also accumulated lactic acid more quickly, leading to greater breathlessness and increased leg discomfort during exercise. Ultrasound scans and blood tests further showed signs of impaired blood vessel function and inflammation.
Dr. Azmy Faisal, senior lecturer in cardiorespiratory physiology at Manchester Metropolitan University and lead author of the study, said, “In active, healthy young adults with normal lungs, both vapes and tobacco smoking led to worsened exercise capacity, shortness of breath, and intense leg fatigue.”
"Like smoking, our research indicates that vaping can lead to harmful changes to the blood vessels, lung efficiency during exercise, and approximately a 15% reduction in fitness compared to those who have never smoked or vaped," Faisal added.
Dr. Stamatoula Tsikrika of the European Respiratory Society commented on the findings, saying the growing popularity of vaping among young people who have never smoked is becoming an increasing public health concern.
Also read: How Smoking, Alcohol, And Vaping Are Quietly Hurting Women’s Fertility
"More and more young people who have never smoked are using vapes," Tsikrika said. "As the popularity of vaping continues to rise, so too do concerns that it is becoming normalised behaviour, functioning as a gateway to nicotine addiction and introducing serious health risks."
She noted that although e-cigarettes may contain fewer cancer-causing substances than conventional cigarettes, they can still lead to significant genetic changes.
"Vapes may contain lower levels of cancer-causing substances, but they can still trigger genetic changes such as DNA damage and inflammation, which are linked to increased lung cancer risk," Tsikrika said. "For people who have never smoked and are therefore not using vapes as a cessation method, the health consequences of vaping are becoming harder for policymakers and the tobacco industry to justify."
Also read: Friends Can Have A Big Impact On Vaping Habits, Study Suggests
The researchers, however, caution that the study does not suggest that vaping is equally harmful as smoking in every respect.
Traditional cigarettes still strongly remain linked to major disorders like cancer, chronic obstructive pulmonary disease (COPD), and many other life-threatening illnesses.
But the new study indicates that when it comes to cardiovascular fitness, breathing efficiency, lung function and blood vessel health in young adults, vaping may offer far less protection.
Credit: AI
The U.S. government's Department of Health and Human Services (HHS) recently announced partnering with the Department of Veterans Affairs (VA) to fast-track the development of psychedelic-assisted therapies to treat veterans living with mental health issues like post-traumatic stress disorder (PTSD), depression, traumatic brain injury (TBI), and more.
After years of interest, 2026 has marked a major policy shift, with the White House, Congress, and the Department of Veterans Affairs (VA) all actively participating in accelerating research into treatments like psilocybin, MDMA, and ibogaine.
“America owes every veteran the best care our nation can provide,” said HHS Secretary Robert F. Kennedy, Jr. “We’re not going to wait while promising treatments sit on the sidelines. Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA-approved innovations and transition them from research into care so veterans can access the treatments they deserve.”
The collaboration comes as a bipartisan group of lawmakers introduced a new bill in Congress that would require the U.S. Department of Defense to evaluate how ongoing psychedelic research, particularly those involving psilocybin, could benefit service members who are active on duty and veterans transitioning back to civilian life.
“President Trump opened up a world of possibility for treating Veterans and others with mental health conditions, and VA is proud to be part of this important work,” said VA Secretary Doug Collins. “Today’s MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment.”
The initiative was accelerated this year in April when President Donald Trump signed an executive order directing federal agencies to ramp up research, regulatory review, and appropriate patient access ways for psychedelic medicines targeting serious mental illnesses.
According to the White House, the goal is to expand the scope of scientific research while ensuring safety and regulatory requirements, rather than recklessly legalizing psychedelic drugs for general medical use.
Most psychedelic compounds, including psilocybin, MDMA, and ibogaine, remain classified as Schedule I substances under federal law.
Mental health challenges remain one of the most pressing issues U.S. veterans face after their military service. They are prioritised because they face a disproportionately high burden of PTSD, depression, suicide, and traumatic brain injury among former service members.
While conventional treatments, including antidepressants and psychotherapy, help many patients, a substantial number do not achieve lasting relief.
Researchers hope psychedelic-assisted therapy, administered under carefully supervised clinical settings alongside psychotherapy, may offer another option for people who are still struggling despite existing treatments.
The interest in psychedelic medicine has grown rapidly over the past decade. Studies have suggested that MDMA-assisted psychotherapy may help alleviate PTSD symptoms in some patients, while psilocybin-assisted therapy has shown promise for treatment-resistant depression in clinical trials.
These therapies differ from recreational drug use because they involve carefully screened patients, controlled doses, trained therapists, and structured treatment plan and follow-up sessions.
Credit: iStock
The World Health Organization (WHO) has validated El Salvador for eliminating trachoma, the world's leading infectious cause of blindness, as a public health problem.
El Salvador is the first country in Central America and the second in the Americas to achieve this milestone.
"I congratulate El Salvador on this remarkable achievement. It is a testament to the power of political commitment, strategic investment, and community engagement," said WHO Director-General Dr Tedros Adhanom Ghebreyesus.
"El Salvador's success is a vital step towards our global target of eliminating trachoma worldwide by 2030 and a clear signal that a healthier, more equitable future is within reach," he added.
Also read: US Appeals Court Revives Over 500 Tylenol Lawsuits Over Autism Claims
Between 2023 and 2026, El Salvador conducted targeted assessments in communities identified as at higher environmental and social risk. The surveys found no evidence of active trachoma transmission.
As per the WHO, "no cases of active disease were detected in children, and no adults were found to have advanced trachoma capable of causing blindness". These findings confirmed that trachoma is no longer a public health problem in the country, the UN health agency said.
El Salvador's achievement was supported by a coordinated approach that included:
The country has also established trained health personnel, integrated surveillance systems and the capacity to detect and treat trichiasis—the advanced stage of trachoma in which eyelashes turn inward and can lead to blindness.
Trachoma is a bacterial eye infection caused by Chlamydia trachomatis. It can spread from person to person through contaminated fingers, fomites and flies that could come into contact with discharge from the eyes or nose of an infected person.
Environmental risks like poor hygiene, overcrowded households, and inadequate access to water and sanitation facilities can also lead to trachoma.
Repeated infections can scar the inner eyelid, causing the eyelashes to turn inward—a condition known as trichiasis. Without treatment, the eyelashes scratch the surface of the eye, potentially leading to irreversible blindness.
Read More: Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds
Although El Salvador has eliminated trachoma as a public health problem, the disease remains endemic in rural and remote areas of Brazil, Colombia, Guatemala and Peru.
WHO recommends that countries maintaining elimination continue surveillance and ensure access to quality eye care services to prevent the disease from re-emerging.
WHO defines elimination of trachoma as a public health problem based on three key criteria:
With this achievement, El Salvador joins 64 countries worldwide that have been validated by WHO for eliminating at least one neglected tropical disease. Seven of these countries are in the Americas.
© 2024 Bennett, Coleman & Company Limited